ROBERT F. CAREY - Corporate Board Profile

SANGAMO THERAPEUTICS, INC

Filing Date	Source Excerpt
2016-04-25	Robert F. Carey, age 57, is a new director nominee. Mr. Carey has been executive vice president, chief business officer for Horizon Pharma plc, a biopharmaceutical company, since March 2014. ... Mr. Carey has served on the board of directors of Argos Therapeutics, Inc., a life science company, since September 2015.
2017-04-25	Robert F. Carey, age 58, has served as a member of our Board of Directors since June 2016. Mr. Carey has been executive vice president, chief business officer for Horizon Pharma plc... The Audit Committee consists of three directors: Mr. Carey, Mr. Ringo and Ms. Ramasastry.
2018-04-24	Robert F. Carey, age 59, has served as a member of our Board of Directors since June 2016. The Audit Committee consists of three directors: Mr. Carey, Ms. Ramasastry, and Mr. Zakrzewski. Mr. Carey serves as the Chairman of this committee. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2017. Robert F. Carey: Total $105,718.
2019-04-25	Robert F. Carey, age 60, has served as a member of our Board of Directors since June 2016. The Audit Committee consists of three directors: Mr. Carey, Ms. Ramasastry, and Mr. Zakrzewski. Mr. Carey serves as the Chairman of this committee. Director compensation table shows total compensation of $250,270.
2020-04-02	Robert F. Carey, age 61, has served as a member of our Board of Directors since June 2016. Mr. Carey served as executive vice president, chief business officer for Horizon Pharma plc, a biopharmaceutical company, from March 2014 to October 2019. The Audit Committee consists of three directors: Mr. Carey, Dr. Dilly and Ms. Ramasastry. Mr. Carey serves as the Chairman of this committee. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2019. Mr. Carey received total compensation of $176,312.
2021-04-02	Robert F. Carey, age 62, has served as a member of our Board of Directors since June 2016. Mr. Carey has served as co-founder, president and chief operating officer of ACELYRIN, Inc., a privately-held biopharmaceutical company, since July 2020. Mr. Carey has served as Executive Vice President, Chief Business Officer for Horizon Therapeutics plc, a biopharmaceutical company, from March 2014 to October 2019. Prior to that, he served as managing director and head of the healthcare investment banking group at JMP Securities LLC, a full-service investment bank from 2003 to 2014. Prior to JMP, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities International, Inc. He has also held roles at Shearson Lehman Hutton and Ernst & Whinney. Mr. Carey also serves on the board of directors of Beyond Air, Inc. (formerly AIT Therapeutics, Inc.), a public medical device and biopharmaceutical company. Mr. Carey previously served on the board of directors of FS Development Corp., a public blank-check company now known as Gemini Therapeutics, Inc., from July 2020 to February 2021. Mr. Carey received his BBA in accountancy from the University of Notre Dame. The Nominating and Corporate Governance Committee and the Board believe that Mr. Carey’s extensive experience and knowledge in the healthcare investment banking industry, particularly with financings, global expansion and other strategic transactions by life-science companies, as well as his role in senior management and business development for a public biopharmaceutical company, provides the Board with valuable insight and contribution. The Audit Committee consists of three directors: Mr. Carey, Mr. Meyers and Ms. Ramasastry. Mr. Carey serves as the Chair of this committee. The Audit Committee held four meetings during 2020. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2020. Mr. Carey received total compensation of $300,172.
2022-04-01	Robert F. Carey, age 63, has served as a member of our Board of Directors since June 2016. The Audit Committee consists of three directors: Mr. Carey, Mr. Meyers and Ms. Ramasastry. Mr. Carey serves as the Chair of this committee. The following table sets forth certain information regarding the compensation of each non-employee director for service as a member of the Board of Directors during 2021. Mr. Carey total compensation was $273,062.
2023-04-17	Robert F. Carey, age 64, has served as a member of our Board of Directors since June 2016. Mr. Carey has served as co-founder and president of ACELYRIN, Inc., a privately-held biopharmaceutical company, since July 2020. ... The Board of Directors has determined that Mr. Carey is an “audit committee financial expert” as defined under SEC rules and that each member of the Audit Committee has the requisite financial sophistication in accordance with the applicable Nasdaq listing standards.
2024-04-19	Robert F. Carey, age 65, has served as a member of our Board of Directors since June 2016. ... Audit Committee members include Mr. Carey (Chair). ... Director compensation table shows Robert F. Carey total compensation as $80,531.